About Us
Research
Support
Giving & Events
Contact Us
Donate
Text Size
Contact Us
About Us
Our Background
Charity Origins
YBTC Impact Report 2019
YBTC Impact Report 2020
YBTC Impact Report 2021
The Good Business Charter
Our Team
Join Team YBTC
Meet Our Team
Meet Our Patrons & Celebrity Ambassadors
Meet Our Ambassadors
Meet Our Volunteers
Beefy's Charity Foundation
Current Funds
Safeguarding
Research
Research
Latest Research News!
Background to research
Current Research
Previous Research Stories
Donating tissue for research
Donating tissue after death
Support
Support Services
Peer Support Groups
Peer Support Walks
YBTC Support Line
Other Resources
Signs & Symptoms of a brain tumour
Managing anxiety before a scan
Travelling abroad after a diagnosis
Driving & transport after your diagnosis
Radiotherapy Masks
The Brain Tumour Patients' Charter of Rights
Giving & Events
Loving Events
Get Involved
At Your Own Pace Challenge
Loving Shopping
YBTC Online Shop
Loving Giving
Regular Giving
Remember a loved one
Leaving a gift in your will
Contact Us
Research News (1)
Research News
Thu 25 February
Research might pave
the way for future drug trials that aim to improve the effectiveness of our current treatments for high-grade brain tumours, and give patients and their families some much needed improvements in survival rates.
The work from Natasha Carmell's YBTC supported PhD has just been published this week:
Glioblastomas are high-grade brain tumours and are the most common form of malignancy arising in the brain. Patient survival has improved little over the last 40 years, highlighting an urgent unmet need for more effective treatments for these tumours.
The current standard-of-care treatment involves surgical removal of as much of the tumour as possible, followed by a course of chemotherapy or radiotherapy. The main chemotherapeutic drug used is called temozolomide, taken as a tablet.
However even with this treatment regimen, the average patient survival following diagnosis is around 15 months. This research has identified a protein called ERK5 which is present at higher levels in these high-grade brain tumours compared to normal brain tissue, and which is also associated with resistance to temozolomide and poor patient survival.
Additionally, they have shown that targeting ERK5 in brain tumour cells can improve the effectiveness of temozolomide in killing these tumour cells and offers potential much-needed future clinical benefit to patients diagnosed with glioblastoma.
To see a full copy of the research "Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma", please
CLICK HERE.
To see more about Natasha's funded PhD, please
CLICK HERE.
Since 2003 you've helped us raise:
4,807,665.73
Helpful Links
Registered Charity No. 1095931
Contact Us
Office: 0113 340 0111
Email:
info@yorksbtc.org.uk
Find Us
Yorkshire's Brain Tumour Charity
31 Otley Road,
Headingley,
Leeds,
LS6 3AA
Yorkshire's Brain Tumour Charity, Registered Charity Address 31 Otley Road, Headingley, Leeds, LS6 3AA.
© Yorkshire's Brain Tumour Charity. Registered Charity No. 1095931
Privacy Policy
|
Cookie Policy
|
Refund Policy
|
Fundraising Promise
|
Complaints Policy
|
Covid-19
by pixelbuilders.com |
digital agency leeds
Make a Donation